Histone Deacetylase Inhibitors Induce TAP, LMP, Tapasin Genes and MHC Class I Antigen Presentation by Melanoma Cells

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2007 Nov 30

PMID 18046553

Citations 117

Authors

A Nazmul H Khan

Christopher J Gregorie

Thomas B Tomasi

Affiliations

Soon will be listed here.

Abstract

Histone deacetylase inhibitors (HDACi), including trichostatin A (TSA) and valproic acid, can alter the acetylation of histones in chromatin and enhance gene transcription. Previously we demonstrated that HDACi-treated tumor cells are capable of presenting antigen via the MHC class II pathway. In this study, we show that treatment with HDACi enhances the expression of molecules (TAP1, TAP2, LMP2, LMP7, Tapasin and MHC class I) involved in antigen processing and presentation via the MHC class I pathway in melanoma cells. HDACi treatment of B16F10 cells also enhanced cell surface expression of class I and costimulatory molecules CD40 and CD86. Enhanced transcription of these genes is associated with a significant increase in direct presentation of whole protein antigen and MHC class I-restricted peptides by TSA-treated B16F10 cells. Our data indicate that epigenetic modification can convert a tumor cell to an antigen presenting cell capable of activating IFN-gamma secreting T cells via the class I pathway. These findings suggest that the abnormalities, observed in some tumors in the expression of MHC class I antigen processing and presentation molecules, may result from epigenetic repression.

Citing Articles

The Novel HDAC Inhibitor OBP-801 Promotes MHC Class I Presentation Through LMP2 Upregulation, Enhancing the PD-1-Targeting Therapy in Clear Cell Renal Cell Carcinoma.

Narukawa T, Yasuda S, Horinaka M, Taniguchi K, Tsujikawa T, Morita M Cancers (Basel). 2024; 16(23).

PMID: 39682244 PMC: 11640654. DOI: 10.3390/cancers16234058.

Immunotherapy in melanoma: advances, pitfalls, and future perspectives.

Sorino C, Iezzi S, Ciuffreda L, Falcone I Front Mol Biosci. 2024; 11:1403021.

PMID: 39086722 PMC: 11289331. DOI: 10.3389/fmolb.2024.1403021.

Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities.

Yin N, Li X, Zhang X, Xue S, Cao Y, Niedermann G Signal Transduct Target Ther. 2024; 9(1):126.

PMID: 38773064 PMC: 11109181. DOI: 10.1038/s41392-024-01826-z.

Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer.

Zhu Q, Dai Q, Zhao L, Zheng C, Li Q, Yuan Z Cell Death Dis. 2024; 15(1):10.

PMID: 38182579 PMC: 10770036. DOI: 10.1038/s41419-023-06303-z.

Epigenome-Driven Strategies for Personalized Cancer Immunotherapy.

Rocha G, Gomes J, Leite M, da Cunha N, Costa F Cancer Manag Res. 2023; 15:1351-1367.

PMID: 38058537 PMC: 10697012. DOI: 10.2147/CMAR.S272031.

References

Seliger B, Wollscheid U, Momburg F, Blankenstein T, Huber C . Coordinate downregulation of multiple MHC class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin. Tissue Antigens. 2000; 56(4):327-36. DOI: 10.1034/j.1399-0039.2000.560404.x. View

Luo W, Wang X, Kageshita T, Wakasugi S, Karpf A, Ferrone S . Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells. Oncogene. 2006; 25(20):2873-84. DOI: 10.1038/sj.onc.1209319. View

Jenuwein T, Allis C . Translating the histone code. Science. 2001; 293(5532):1074-80. DOI: 10.1126/science.1063127. View

Lin H, Chen C, Lin S, Weng J, Chen C . Targeting histone deacetylase in cancer therapy. Med Res Rev. 2006; 26(4):397-413. DOI: 10.1002/med.20056. View

Evans M, Borysiewicz L, Evans A, Rowe M, Jones M, Gileadi U . Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. J Immunol. 2001; 167(9):5420-8. DOI: 10.4049/jimmunol.167.9.5420. View

Johnstone R, Licht J . Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?. Cancer Cell. 2003; 4(1):13-8. DOI: 10.1016/s1535-6108(03)00165-x. View

Maeda T, Towatari M, Kosugi H, Saito H . Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood. 2000; 96(12):3847-56. View

Armeanu S, Bitzer M, Lauer U, Venturelli S, Pathil A, Krusch M . Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 2005; 65(14):6321-9. DOI: 10.1158/0008-5472.CAN-04-4252. View

Magner W, Kazim A, Stewart C, Romano M, Catalano G, Grande C . Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol. 2000; 165(12):7017-24. DOI: 10.4049/jimmunol.165.12.7017. View

10.

Ogino T, Shigyo H, Ishii H, Katayama A, Miyokawa N, Harabuchi Y . HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res. 2006; 66(18):9281-9. DOI: 10.1158/0008-5472.CAN-06-0488. View

11.

Zhao B, Hou S, Ricciardi R . Chromatin repression by COUP-TFII and HDAC dominates activation by NF-kappaB in regulating major histocompatibility complex class I transcription in adenovirus tumorigenic cells. Virology. 2003; 306(1):68-76. DOI: 10.1016/s0042-6822(02)00079-x. View

12.

Baylin S, Ohm J . Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat Rev Cancer. 2006; 6(2):107-16. DOI: 10.1038/nrc1799. View

13.

Schoenhals G, Krishna R, Grandea 3rd A, Spies T, Peterson P, Yang Y . Retention of empty MHC class I molecules by tapasin is essential to reconstitute antigen presentation in invertebrate cells. EMBO J. 1999; 18(3):743-53. PMC: 1171167. DOI: 10.1093/emboj/18.3.743. View

14.

Hogquist K, Jameson S, Heath W, Howard J, Bevan M, Carbone F . T cell receptor antagonist peptides induce positive selection. Cell. 1994; 76(1):17-27. DOI: 10.1016/0092-8674(94)90169-4. View

15.

Fonsatti E, Sigalotti L, Coral S, Colizzi F, Altomonte M, Maio M . Methylation-regulated expression of HLA class I antigens in melanoma. Int J Cancer. 2003; 105(3):430-1; author reply 432-3. DOI: 10.1002/ijc.11077. View

16.

Raffaghello L, Prigione I, Bocca P, Morandi F, Camoriano M, Gambini C . Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene. 2005; 24(29):4634-44. DOI: 10.1038/sj.onc.1208594. View

17.

Agrawal S, Reemtsma K, Bagiella E, Oluwole S, Braunstein N . Role of TAP-1 and/or TAP-2 antigen presentation defects in tumorigenicity of mouse melanoma. Cell Immunol. 2004; 228(2):130-7. DOI: 10.1016/j.cellimm.2004.04.006. View

18.

Lou Y, Vitalis T, Basha G, Cai B, Chen S, Choi K . Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival. Cancer Res. 2005; 65(17):7926-33. DOI: 10.1158/0008-5472.CAN-04-3977. View

19.

Schoenberger S, Jonges L, Mooijaart R, Hartgers F, Toes R, Kast W . Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC. Cancer Res. 1998; 58(14):3094-100. View

20.

Jimenez P, Canton J, Concha A, Cabrera T, Fernandez M, Real L . Microsatellite instability analysis in tumors with different mechanisms for total loss of HLA expression. Cancer Immunol Immunother. 2001; 48(12):684-90. PMC: 11037143. DOI: 10.1007/s002620050017. View